Try our beta test site

First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

This study has been terminated.
(Trial discontinued due to apparent lack of response in psoriasis measures. No safety concerns were present)
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT01261767
First received: December 14, 2010
Last updated: February 8, 2017
Last verified: February 2017